The present invention refers to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. The invention refers also to pharmaceutical compositions comprising these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.
released through an enzyme‐initiated 1,6‐elimination reaction. Optimisation of the stereoelectronic properties and of the binding interactions at the enzyme active site led to substrates with highaffinity and promising selectivity.
Substituted Quinazoline or Pyridopyrimidine Derivative
申请人:Mitsuya Morihiro
公开号:US20080032996A1
公开(公告)日:2008-02-07
The present invention provides a compound having a glucokinase activating action being useful for prevention or treatment of diabetes mellitus, etc. being represented by the formula (I):
X is nitrogen atom, etc.; Y is oxygen atom, etc.; R
1
is an optionally substituted five to six-membered heteroaryl group, etc.; R
2
is hydrogen atom or fluorine atom; and ring A is a monocyclic or bicyclic heteroaryl group which may have a substituent represented by the formula (II)]
or a pharmaceutically acceptable salt thereof.
SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
申请人:BANYU PHARMACEUTICAL CO., LTD.
公开号:EP1734040A1
公开(公告)日:2006-12-20
The present invention provides a compound having a glucokinase activating action being useful for prevention or treatment of diabetes mellitus, etc. being represented by the formula (I):
X is nitrogen atom, etc.; Y is oxygen atom, etc.; R1 is an optionally substituted five to six-membered heteroaryl group, etc.; R2 is hydrogen atom or fluorine atom; and ring A is a monocyclic or bicyclic heteroaryl group which may have a substituent represented by the formula (II)]
or a pharmaceutically acceptable salt thereof.